Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

newcleo books roughly €10M quarterly sales and holds €233M cash as prototype core completes

The Nasdaq-listed nuclear developer reports preliminary third-quarter numbers, a finished core at its Italian test unit, two industrial moves and a favourable French regulatory view.

18 Nov 2026 · newcleo plc NWCL · Company news

newcleo (Nasdaq: NWCL), which develops nuclear reactors and mixed-oxide (MOX) fuel, put out preliminary third-quarter figures on 18 November. Sales from its products and services came to about €10.0M, which the company says is 26% higher. It did not provide the comparison figure in the material we reviewed. Cash on 30 September was €233.4M.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): newcleo plc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →